Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Merrimack Pharmaceuticals, Inc. (MACK : NSDQ)

• Company Description    Merrimack Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery, development and preparation to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with a special focus on cancer. Merrimack Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $5.25 Daily Weekly Monthly 20 Day Moving Average: 10,077 shares Shares Outstanding: 13.41 (millions) Market Capitalization: $70.40 (millions) Beta: 1.68 52 Week High: $7.41 52 Week Low: $3.66 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -7.24% 1.56% 12 Week -16.73% -6.42% Year To Date 34.27% 64.04%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL ONE BROADWAY 14TH FLOOR - CAMBRIDGE,MA 02142 USA ph: 617-441-1000 fax: 617-491-1386 ir@merrimack.com http://www.merrimackpharma.com

• General Corporate Information    Officers Gary L. Crocker - President and Chairman of the Board Eric D. Andersen - Director Noah G. Levy - Director Ulrik B. Nielsen - Director Russell T. Ray - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 590328209 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/04/22 Share - Related Items Shares Outstanding: 13.41 Most Recent Split Date: 9.00 (0.10:1) Beta: 1.68 Market Capitalization: $70.40 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 5.00 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 20.00% vs. Previous Quarter: -33.33% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -16.12 12/31/21 - -16.46 09/30/21 - -20.09 ROA 03/31/22 - -15.43 12/31/21 - -15.75 09/30/21 - -19.18 Current Ratio 03/31/22 - 25.91 12/31/21 - 26.13 09/30/21 - 22.25 Quick Ratio 03/31/22 - 25.91 12/31/21 - 26.13 09/30/21 - 22.25 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 1.05 12/31/21 - 1.06 09/30/21 - 1.09 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©